Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer : a randomized, controlled, double-blind phase 3 trial
© 2022. The Author(s)..
First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously shown significant improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with advanced non-small cell lung cancer (aNSCLC) and PD-ligand 1 (PD-L1) expression ≥50%. EMPOWER-Lung 3 ( NCT03409614 ), a double-blind, placebo-controlled, phase 3 study, examined cemiplimab plus platinum-doublet chemotherapy as first-line treatment for aNSCLC, irrespective of PD-L1 expression or histology. In this study, 466 patients with stage III/IV aNSCLC without EGFR, ALK or ROS1 genomic tumor aberrations were randomized (2:1) to receive cemiplimab 350 mg (n = 312) or placebo (n = 154) every 3 weeks for up to 108 weeks in combination with four cycles of platinum-doublet chemotherapy (followed by pemetrexed maintenance as indicated). In total, 57.1% (266/466 patients) had non-squamous NSCLC, and 85.2% (397/466 patients) had stage IV disease. The primary endpoint was OS. The trial was stopped early per recommendation of the independent data monitoring committee, based on meeting preset OS efficacy criteria: median OS was 21.9 months (95% confidence interval (CI), 15.5-not evaluable) with cemiplimab plus chemotherapy versus 13.0 months (95% CI, 11.9-16.1) with placebo plus chemotherapy (hazard ratio (HR) = 0.71; 95% CI, 0.53-0.93; P = 0.014). Grade ≥3 adverse events occurred with cemiplimab plus chemotherapy (43.6%, 136/312 patients) and placebo plus chemotherapy (31.4%, 48/153 patients). Cemiplimab is only the second anti-PD-1/PD-L1 agent to show efficacy in aNSCLC as both monotherapy and in combination with chemotherapy for both squamous and non-squamous histologies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Nature medicine - 28(2022), 11 vom: 25. Nov., Seite 2374-2380 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gogishvili, Miranda [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.11.2022 Date Revised 12.01.2023 published: Print-Electronic ClinicalTrials.gov: NCT03409614 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-022-01977-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345271211 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345271211 | ||
| 003 | DE-627 | ||
| 005 | 20231226024702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-022-01977-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1150.xml |
| 035 | |a (DE-627)NLM345271211 | ||
| 035 | |a (NLM)36008722 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gogishvili, Miranda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer |b a randomized, controlled, double-blind phase 3 trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.11.2022 | ||
| 500 | |a Date Revised 12.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03409614 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously shown significant improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with advanced non-small cell lung cancer (aNSCLC) and PD-ligand 1 (PD-L1) expression ≥50%. EMPOWER-Lung 3 ( NCT03409614 ), a double-blind, placebo-controlled, phase 3 study, examined cemiplimab plus platinum-doublet chemotherapy as first-line treatment for aNSCLC, irrespective of PD-L1 expression or histology. In this study, 466 patients with stage III/IV aNSCLC without EGFR, ALK or ROS1 genomic tumor aberrations were randomized (2:1) to receive cemiplimab 350 mg (n = 312) or placebo (n = 154) every 3 weeks for up to 108 weeks in combination with four cycles of platinum-doublet chemotherapy (followed by pemetrexed maintenance as indicated). In total, 57.1% (266/466 patients) had non-squamous NSCLC, and 85.2% (397/466 patients) had stage IV disease. The primary endpoint was OS. The trial was stopped early per recommendation of the independent data monitoring committee, based on meeting preset OS efficacy criteria: median OS was 21.9 months (95% confidence interval (CI), 15.5-not evaluable) with cemiplimab plus chemotherapy versus 13.0 months (95% CI, 11.9-16.1) with placebo plus chemotherapy (hazard ratio (HR) = 0.71; 95% CI, 0.53-0.93; P = 0.014). Grade ≥3 adverse events occurred with cemiplimab plus chemotherapy (43.6%, 136/312 patients) and placebo plus chemotherapy (31.4%, 48/153 patients). Cemiplimab is only the second anti-PD-1/PD-L1 agent to show efficacy in aNSCLC as both monotherapy and in combination with chemotherapy for both squamous and non-squamous histologies | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a cemiplimab |2 NLM | |
| 650 | 7 | |a 6QVL057INT |2 NLM | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Platinum |2 NLM | |
| 650 | 7 | |a 49DFR088MY |2 NLM | |
| 650 | 7 | |a Protein-Tyrosine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
| 700 | 1 | |a Melkadze, Tamar |e verfasserin |4 aut | |
| 700 | 1 | |a Makharadze, Tamta |e verfasserin |4 aut | |
| 700 | 1 | |a Giorgadze, Davit |e verfasserin |4 aut | |
| 700 | 1 | |a Dvorkin, Mikhail |e verfasserin |4 aut | |
| 700 | 1 | |a Penkov, Konstantin |e verfasserin |4 aut | |
| 700 | 1 | |a Laktionov, Konstantin |e verfasserin |4 aut | |
| 700 | 1 | |a Nemsadze, Gia |e verfasserin |4 aut | |
| 700 | 1 | |a Nechaeva, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Rozhkova, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Kalinka, Ewa |e verfasserin |4 aut | |
| 700 | 1 | |a Gessner, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno-Jaime, Brizio |e verfasserin |4 aut | |
| 700 | 1 | |a Passalacqua, Rodolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Siyu |e verfasserin |4 aut | |
| 700 | 1 | |a McGuire, Kristina |e verfasserin |4 aut | |
| 700 | 1 | |a Kaul, Manika |e verfasserin |4 aut | |
| 700 | 1 | |a Paccaly, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Quek, Ruben G W |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Seebach, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Weinreich, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Yancopoulos, George D |e verfasserin |4 aut | |
| 700 | 1 | |a Lowy, Israel |e verfasserin |4 aut | |
| 700 | 1 | |a Gullo, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Rietschel, Petra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 28(2022), 11 vom: 25. Nov., Seite 2374-2380 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:11 |g day:25 |g month:11 |g pages:2374-2380 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-022-01977-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 11 |b 25 |c 11 |h 2374-2380 | ||